Xiushi Bio Secures Tens of Millions in RMB in Angel Funding from Shicui Capital to Accelerate Industrial Application of Its Proprietary Peptide Biosynthesis Platform

Recently, Xiushi Biopharma Co., Ltd. (hereinafter referred to as “XIUSHI”) announced the completion of its angel financing round amounting to tens of millions of yuan. This round was exclusively invested by Shicui Capital, with Linglu Capital serving as the exclusive financial advisor.

The proceeds from this round of financing will be primarily used to further invest in the company’s proprietary innovative peptide biosynthesis technology platform and new product R&D, expand production capacity for existing products, and promote the adoption and application of its leading technologies and products both domestically and internationally.

Founded in 2020, XIUSHI boasts a core team of technical experts in pharmaceutical engineering, fermentation engineering, and protein engineering. Leveraging extensive practical experience in biomanufacturing, the company provides industry partners with novel and highly attractive biosynthetic solutions for peptide drugs. Currently, XIUSHI’s proprietary innovative biosynthesis strategies have undergone scaled-up validation for various short peptides and complex cyclic peptides, offering capacity-building and cost advantages that surpass traditional biological and chemical synthesis methods. This has secured development collaboration orders from numerous renowned downstream pharmaceutical companies and CDMOs. XIUSHI is committed to helping its partners maintain a leading edge in peptide drug discovery and manufacturing process development through innovative biosynthesis technologies.

Regarding this round of financing, Dr. Wu Yinsong, Founder and CEO of XIUSHI“Peptides have emerged as a key focus in novel drug research in recent years and serve as important ingredients in the daily cosmetics sector, offering substantial market potential. However, traditional biosynthesis strategies are constrained by limited underlying technical approaches, making them suitable only for a few types of peptides with extremely low expression levels, thereby keeping capacity investment and overall production costs persistently high. Meanwhile, current mainstream chemical synthesis strategies struggle with long and complex peptides; their intricate and lengthy synthetic steps, coupled with intermediate losses, prevent them from overcoming challenges related to production capacity and cost. XIUSHI is dedicated to building innovative biosynthesis strategies and technology platforms in the peptide field. Over the past two years, we have achieved substantial results in the biosynthesis of short peptides, complex cyclic peptides, and non-naturally modified peptides, earning recognition from numerous downstream manufacturers. We believe that XIUSHI will become a significant driving force in revolutionizing the discovery, development, and manufacturing processes of peptide drugs and novel peptides.”

XIUSHI is deeply honored to have earned the recognition and support of Shicui Capital, a professional healthcare investment institution. The completion of this financing round marks a brand-new starting point for XIUSHI, and we sincerely appreciate the trust and expectations placed in us. We will continue to accelerate the implementation of our core technology platform, expand production capacity, and promote the application and adoption of our products. By collaborating with partners across the upstream and downstream value chain, we aim to jointly drive innovative development in the peptide industry.

Dr. Ning Chenxi, Shicui Capital“Peptide drugs are undoubtedly one of the next hotspots in new drug R&D. Their unique properties, which lie between those of large molecules and small molecules, offer exciting possibilities for addressing numerous complex diseases and provide a vast, underexplored space for innovative pharmaceutical companies. In recent years, the outstanding market performance of a batch of peptide drugs led by semaglutide, as well as the rapid growth of PeptiDream, a leading enterprise in peptide drug discovery, have strongly confirmed this trend. Precisely because peptides possess characteristics intermediate between large and small molecules, traditional biosynthesis and chemical synthesis methods fail to provide perfect solutions for their large-scale production. XIUSHI’s novel biosynthetic system developed specifically for peptides offers a viable solution to effectively address the challenges of large-scale peptide manufacturing. This strategy is expected to overcome two major hurdles in the peptide field: capacity building and comprehensive production costs. It has already achieved large-scale validation across various types of peptides and has received high recognition from downstream customers. We are delighted to partner with XIUSHI and look forward to witnessing the tremendous potential brought by revolutionary technologies in the peptide field.”

Shicui is a spirit that shuns trend-chasing and prejudice, embracing humility and dedication to uncovering true value. Founded by seasoned healthcare investment professionals, Shicui Capital is committed to building a professional brand in early-stage healthcare investment. It empowers outstanding entrepreneurs who master emerging technologies and possess industry consolidation capabilities, driving innovation and transformation in the healthcare sector while delivering genuine investment returns.